search

Active clinical trials for "Leukemia, Lymphocytic, Chronic, B-Cell"

Results 1471-1480 of 1487

Genomic Analysis of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

This study aims to characterize clonal evolution in chronic lymphocytic leukemia (CLL) using different approaches and to identify a possible association with disease progression, i.e. therapy initiation. Samples This monocentric study is carried out using representative bioarchived leukemic samples with a diagnosis of CLL, either at diagnosis or at evolution. These bioarchived samples were collected locally at our center during years of diagnostic activity, and were accurately pathologically, cytogenetically and molecularly characterized. Clinical data The clinical data were retrospectively collected through collaboration with the referring physicians. Methods Samples will be investigated by means of (1) conventional cytogenetics, (2) fluorescence in situ hybridization (FISH) and (3) SNP-arrays. After analysis of the array data sets, significant results will be validated and in addition, results will be correlated with clinical data.

Unknown status3 enrollment criteria

Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic...

Chronic Lymphocytic Leukemia Stage A(0)Chronic Lymphocytic Leukemia Stage A(I)1 more

The purpose of the present study is to develop a biological prognostic index in patients with Binet stage A Chronic Lymphocytic Leukemia (CLL) who do not necessitate therapy according to NCI guidelines and to prospectively validate the proposed score system based on the absence/presence of 1, 2 or 3 unfavorable prognostic markers such as cluster of differentiation 38 (CD38) expression, Zap-70 expression and immunoglobulin heavy chain variable region (IgVH) configuration.

Unknown status15 enrollment criteria

Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and...

Chronic Lymphocytic Leukemia

This study will be a secondary use of data, focusing on patients treated with combination therapy Obi-Clb, R-Clb or R-B, in a non-interventional, open label, national, multicenter setting. Retrospective analysis of data coming from registry database CLLEAR (www.leukemia-cell.org )that capture data on clinical and treatment practices in CLL. Data will be retrospectively analyzed.

Unknown status8 enrollment criteria

Heavy Light Chain in Chronic Lymphocytic Leukemia

CLL

Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which enables improvement in paraprotein detection and monitoring in multiple myeloma and other plasma-cell dyscrasias. The prognostic and biological role of the HLC assay has as yet not been studied in CLL. Aims of the proposed study: To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC) To study the different patterns of Immunoglobulin's subclass antibodies in the serum of patients with CLL and compare them to those of to healthy volunteers. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and ITP)

Unknown status2 enrollment criteria

Treatment of Chronic Lymphocytic Leukemia

LeukemiaLymphocytic2 more

CLL is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal.

Unknown status1 enrollment criteria

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy...

B Cell Lymphocytic LeukemiaB Cell Non-Hodgkin's Lymphoma

This is an observational cohort study of patients with a new diagnosis of B cell Chronic Lymphocytic Leukemia or B cell Non-Hodgkin's Lymphoma who will receive an anti-CD20 monoclonal antibody treatment during the induction phase of their treatment. Throughout the study, patients will have four blood draws at specified time points throughout the study. The initial blood draw will be analysed test patients for Cytomegalovirus and conduct a g-NK cell analysis. The final three blood draws will be conducted to analyse the g-NK cells at specified time points. The objectives of this study are to: 1) characterize the frequency of CMV (+) and g-NK (+) individuals in the B-NHL and B-CLL populations, 2) Determine changes in circulating g-NK cells during and after anti-CD20 monoclonal antibody containing remission induction chemotherapy and 3) Evaluate whether the presence of g-NK cells improve the outcome of anti-CD20 monoclonal antibody containing remission induction treatment of patients with B-NHL or B-CLL.

Unknown status7 enrollment criteria

Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

Chronic Lymphocytic Leukemia

The purpose of the study is to assess the evolution of B cells at a genetic and surface-marker level in high-risk CLL after idelalisib-rituximab treatment. The targeted population includes 20 subjects ages 18 or older diagnosed with high-risk CLL. This will include patients with relapsed or refractory disease who require therapy with idelalisib and rituximab as per FDA label. This is an observational study for peripheral blood samples of these patients collected at pre-determined time points.

Withdrawn14 enrollment criteria

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic...

CLLSLL3 more

The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.

Withdrawn13 enrollment criteria

Expanded Access to Venetoclax

Chronic Lymphocytic Leukemia (CLL)Multiple Myeloma5 more

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available2 enrollment criteria

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

Approved for marketing22 enrollment criteria
1...147148149

Need Help? Contact our team!


We'll reach out to this number within 24 hrs